Table 1 Comparisons of baseline characteristics between ACPA-negative [ACPA (−)] and ACPA-positive [ACPA (+)] groups.

From: A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients

N

ACPA (−)

ACPA (+)

p value

107

447

Age (years)

67.3 ± 13.7

68.0 ± 11.3

0.583

Sex (% female)

82.2

79.0

0.451

Disease duration (years)

10.4 ± 10.1

12.5 ± 11.9

0.082

Body weight (kg)

51.9 ± 11.4

51.1 ± 9.1

0.412

ACPA (U/mL)

4.5 ± 4.2

370.8 ± 545.1

< 0.001

RF positive (%)

44.6

82.7

< 0.001

eGFR

71.8 ± 24.9

73.4 ± 25.0

0.547

KL-6 (U/mL)

308.6 ± 263.9

339.3 ± 272.6

0.367

Concomitant MTX use (%)

49.0

41.2

0.162

MTX dose (mg/week)a

9.0 ± 3.0

8.6 ± 3.5

0.550

Oral PSL use (%)

44.9

52.9

0.160

Oral PSL dose (mg/day)a

5.6 ± 3.1

5.5 ± 3.3

0.881

Previous biologics (%)

68.2

72.0

0.434

No. previous biologicsa

1.5 ± 0.9

1.6 ± 0.8

0.813

SDAI

20.8 ± 14.0

22.2 ± 12.7

0.381

TJC, 0–28

5.6 ± 5.7

5.5 ± 5.2

0.796

SJC, 0–28

4.5 ± 4.6

4.9 ± 4.7

0.485

PtGA, 0–10 cm

4.9 ± 2.8

5.2 ± 2.6

0.238

PhGA, 0–10 cm

4.1 ± 2.6

4.2 ± 2.2

0.682

CRP (mg/dL)

2.0 ± 2.6

2.4 ± 3.9

0.326

MMP-3 (ng/mL)

191.9 ± 243.2

190.8 ± 200.8

0.966

mHAQ

0.85 ± 0.71

0.83 ± 0.68

0.860

mTSS

64.0 ± 65.8

71.8 ± 87.7

0.631

  1. ACPA anti-citrullinated protein/peptide antibody, RF rheumatoid factor, eGFR estimated glomerular filtration rate, KL-6 Krebs von den Lungen-6, MTX methotrexate, PSL prednisolone, SDAI simplified disease activity index, TJC tender joint count, SJC swollen joint count, PtGA patient’s global assessment, PhGA physician’s global assessment, CRP C-reactive protein, MMP-3 matrix metalloproteinase-3, mHAQ modified health assessment questionnaire, mTSS van der Heijde modified total Sharp score.
  2. aMean among patients receiving the drug.
Back to article page